Back to Peptides

KPV

Immune Modulation

KPV (Lys-Pro-Val) is a tripeptide derived from alpha-MSH with strong anti-inflammatory, antimicrobial, and antifungal properties. It is being explored for use in inflammatory bowel diseases, topical inflammatory skin conditions, and systemic inflammation. Multiple delivery routes have been studied, including oral, SubQ, and topical forms.

Reconstitute
3 mL BAC + 10mg vial
33 mcg/unit
Daily Range
100–500 mcg Oral
Daily
Standard Dose
250 mcg
Cycle
4–8 weeks
then reassess
anti-inflammatoryantimicrobialulcerative colitisCrohn’sKPV peptide

Dosing & Reconstitution Guide

In rodent studies, KPV has been administered orally or topically at 1–5 mg/kg. No approved use exists for humans.

Standard / Gradual Approach

10mg Vialstandard
PhaseDoseVolume
Week 1200 mcg6 units (0.06 mL)
Week 2300 mcg9 units (0.09 mL)
Week 3400 mcg12 units (0.12 mL)
Weeks 4–8500 mcg15 units (0.15 mL)

Protocol Summary

Oral: Daily · Dose range 100–500 mcg with gradual titration
Subcutaneous (SQ): daily · Dose range 100–500 mcg with gradual titration
Cycle Length: 4–8 weeks typical; reassess before extending

Frequency & Cycling

Oral

Typical dose: 250–500 mcg/day in capsule form. Can be taken long-term under supervision for chronic gut inflammation.

Subcutaneous (SQ)

200–400 mcg daily SubQ recommended for systemic anti-inflammatory effects. Use in 4–8 week cycles with evaluation.

Topical

Apply 2% KPV cream to affected skin areas twice daily. Safe for continuous use in inflammatory skin conditions.

🧪 Quick Start

Vial Size
10 mg
BAC Water
3 mL
Concentration
3300 mcg/unit
Starting Dose
200 mcg (6 units (0.06 mL))
Maintenance Dose
500 mcg (15 units (0.15 mL))

Potential Benefits & Use Cases

KPV is a research-use-only compound not approved for therapeutic application.
Reduces pro-inflammatory cytokines and modulates immune responses in IBD models (preclinical)
Enhances epithelial cell regeneration and tight junction integrity — supports gut barrier function (preclinical)
Multiple routes of administration show activity (oral and subcutaneous) (preclinical)
Supports wound healing through inflammatory modulation (preclinical)
Does not affect melanocyte activity or skin pigmentation unlike full α-MSH (preclinical)
Clinical data Strong preclinical Limited data

Mechanism of Action

→Inhibition of NF-kB activation, blocking inflammatory cascade
→Reduction of pro-inflammatory cytokines such as IL-6 and TNF-α
→Supports mucosal immunity and barrier restoration

Stacking Synergies

+
BPC-157
Enhanced gut healing and epithelial repair
+
TB-500
Broad-spectrum anti-inflammatory synergy with systemic immune modulation

Lifestyle & Optimization

diet

Anti-inflammatory diet (omega-3s, polyphenols, minimal processed foods). Support gut microbiome diversity.

sleep

Sleep 7–9 hours. Stress management.

timing

Consistent dosing schedule. Oral for gut, SubQ for systemic.

exercise

Moderate exercise.

Peptide Research & Preclinical Studies

Evidence-Based Research Findings

Study TitleType
PMC — Alpha-melanocyte stimulating hormone (α-MSH) derived tripeptide KPV anti-inflammatory propertiesReference
PLOS ONE — KPV inhibits experimental colitis via CD98/NF-κB pathwayReference
Science Direct — α-MSH signaling and melanocortin receptors in inflammationReference
Peptides Journal — Anti-inflammatory effects of alpha-MSH fragmentsReference
Journal of Leukocyte Biology — KPV inhibits NF-kappaB translocation in intestinal epithelial cellsReference

Side Effects & Safety

Common Side Effects

• Mild flu-like symptoms (user-reported)
• Temporary orange skin stain from topical application (user-reported)

Long-Term Safety Data

• No dedicated human safety studies exist

🧮 Dose Calculator

Concentration
33.3
mcg/unit
Draw Volume
15
units (0.150 mL)
For a 500 mcg dose, draw 15 units on a U-100 insulin syringe
🧬

Bioavailability & Absorption

SubQ Injection
High bioavailability; bypasses GI degradation
Oral Administration
Moderate when nanoparticle-formulated; subject to first-pass metabolism
Half-Life
Approximately 2 hours
Degradation
Broken down by peptidases; stable in topicals and encapsulated delivery systems
Tissue Specificity
Targets gut epithelium, skin layers, and mucosal immune sites
⚗️

Peptide Details

Molecular Weight
282.38
Formula
C15H26N2O3
Sequence
Lys-Pro-Val
⚖️

Legal Status & Regulatory

RegionStatus
EUNot Approved
FDANot Approved
CanadaNot Approved
AustraliaNot Approved

Storage Instructions

Lyophilized (Powder)
freeze at −20 °C (−4 °F) or below; after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F) and use within 30 days; avoid freeze–thaw cycles
Reconstituted (Mixed)
Refrigerate at 2–8 °C (35.6–46.4 °F); use within approximately 30 days